176 related articles for article (PubMed ID: 34838689)
1. Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19.
Dubé C; Paris-Robidas S; Primakova I; Destexhe E; Ward BJ; Landry N; Trépanier S
Reprod Toxicol; 2022 Jan; 107():69-80. PubMed ID: 34838689
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
Ward BJ; Gobeil P; Séguin A; Atkins J; Boulay I; Charbonneau PY; Couture M; D'Aoust MA; Dhaliwall J; Finkle C; Hager K; Mahmood A; Makarkov A; Cheng MP; Pillet S; Schimke P; St-Martin S; Trépanier S; Landry N
Nat Med; 2021 Jun; 27(6):1071-1078. PubMed ID: 34007070
[TBL] [Abstract][Full Text] [Related]
4. Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines.
Dubé C; Paris-Robidas S; Andreani G; Gutzeit C; D'Aoust MA; Ward BJ; Trépanier S
Vaccine; 2022 Jun; 40(30):4017-4025. PubMed ID: 35654621
[TBL] [Abstract][Full Text] [Related]
5. AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.
Grigoryan L; Feng Y; Bellusci L; Lai L; Wali B; Ellis M; Yuan M; Arunachalam PS; Hu M; Kowli S; Gupta S; Maysel-Auslender S; Maecker HT; Samaha H; Rouphael N; Wilson IA; Moreno AC; Suthar MS; Khurana S; Pillet S; Charland N; Ward BJ; Pulendran B
Sci Immunol; 2024 Apr; 9(94):eadi8039. PubMed ID: 38579013
[TBL] [Abstract][Full Text] [Related]
6. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
[TBL] [Abstract][Full Text] [Related]
7. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
Madan A; Segall N; Ferguson M; Frenette L; Kroll R; Friel D; Soni J; Li P; Innis BL; Schuind A
J Infect Dis; 2016 Dec; 214(11):1717-1727. PubMed ID: 27609809
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
10. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.
Cohet C; van der Most R; Bauchau V; Bekkat-Berkani R; Doherty TM; Schuind A; Tavares Da Silva F; Rappuoli R; Garçon N; Innis BL
Vaccine; 2019 May; 37(23):3006-3021. PubMed ID: 31031030
[TBL] [Abstract][Full Text] [Related]
11. Lack of effects on fertility and developmental toxicity of a quadrivalent HPV vaccine in Sprague-Dawley rats.
Wise LD; Wolf JJ; Kaplanski CV; Pauley CJ; Ledwith BJ
Birth Defects Res B Dev Reprod Toxicol; 2008 Dec; 83(6):561-72. PubMed ID: 19025783
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
13. Lack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccine.
Bowman CJ; Bouressam M; Campion SN; Cappon GD; Catlin NR; Cutler MW; Diekmann J; Rohde CM; Sellers RS; Lindemann C
Reprod Toxicol; 2021 Aug; 103():28-35. PubMed ID: 34058573
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
Madan A; Ferguson M; Sheldon E; Segall N; Chu L; Toma A; Rheault P; Friel D; Soni J; Li P; Innis BL; Schuind A
Vaccine; 2017 Mar; 35(10):1431-1439. PubMed ID: 28187952
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.
Madan A; Ferguson M; Rheault P; Seiden D; Toma A; Friel D; Soni J; Li P; Innis BL; Schuind A
Vaccine; 2017 Apr; 35(15):1865-1872. PubMed ID: 28302407
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
19. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.
Mallett CP; Beaulieu E; Joly MH; Baras B; Lu X; Liu F; Levine MZ; Katz JM; Innis BL; Giannini SL
Vaccine; 2015 Jul; 33(32):3784-7. PubMed ID: 26100923
[TBL] [Abstract][Full Text] [Related]
20. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
